|
|
Table 2.
Independent factors associated with core
antibody breakthrough
infection
|
|
| Variable |
No (%) of breakthrough
infections |
Adjusted odds ratio (95%
CI) |
P value for
variable |
|
| Vaccination group (median time (years)
since vaccination): |
| Group 1 (13.6) |
21/52 (40) |
8.9 (3.8 to
20.8) |
0.0001 |
| Group 2 (13.6) |
18/56 (32) |
9.0 (3.8 to 21.1) |
| Group 3 (13.6) |
14/63 (22) |
7.7 (3.2 to 18.5) |
| Group 4 (10.7) |
25/220 (11) |
3.3 (1.6 to 7.1) |
| Group 5 (6.3) |
9/202 (4) |
1.3 (0.5 to 3.3) |
| Group 6 (2.1) |
15/254 (6) |
1.0 |
| Sex: |
|
|
|
| Male |
60/426
(14) |
1.6 (1.0 to 2.6) |
0.04 |
| Female |
42/421
(10) |
1.0 |
| Peak antibody (mIU/ml): |
| <10 |
19/39
(49) |
11.9 (4.9 to 28.8) |
0.0001 |
| 10-99 |
12/58
(21) |
3.4 (1.5 to 7.8) |
| 100-999 |
36/224 (16) |
1.8 (1.0 to
3.2) |
 1000 |
33/449 (7) |
1.0 |
| Village: |
|
|
|
| Manduar |
34/223 (15) |
1.8 (1.1 to
3.0) |
0.03 |
| Keneba |
68/624 (11) |
1.0 |
|